Evaluation of Gestrinone after Surgery in Treatment of Endometriosis

Abstract

Objective: The clinical and histological efficacy of gestrinone in the treatment of endometriosis was evaluated. Methods: A prospective study was performed with longitudinal follow-up of 4 years duration (minimum) for each patient. Twenty-five cases of endometriosis were treated with gestrinone (as a drug of choice or associated with other local surgical treatment) during 6 months. Results: The total or partial response to pain was induced with treatment in 19 of the 20 cases (95%), and posttreatment pregnancies were induced in 3 of the 9 cases of infertility (33.3%). The global clinical efficacy was as follows: none (n = 5,20%), poor (n = 2, 8%), moderate (n = 2, 8%), good (n = 3, 12%) and excellent (n = 13, 52%). The pretreatment American Fertility Society score was 23.1 ± 3.8 points (2–58) and that after treatment (re-examination) 7.8 ± 3.7 points (0–52), p < 0.01. Global histological efficacy (n = 17) results were as follows: none (23.6%), poor (0%), moderate (5.8%), good (35.3%) and excellent (35.3%). Conclusions: Gestrinone is presented as a drug with an efficacy comparable to other pharmacological agents currently available in the medical treatment of endometriosis. Adequate posology and acceptable effectiveness were also observed.

Effects of gestrinone on uterine leiomyoma and expression of c-Src in a guinea pig model

“…Gestrinone was developed originally as a long-acting contraceptive. Because of its marked inhibitory effects on ER and PR in the endometrium and uterus, gestrinone has also been clinically applied to treat endometriosis and uterine leiomyoma with success [27,28] . Marca et al demonstrated that gestrinone significantly increased blood flow impedance of the uterine artery [29] .…”